Journal of Neural Transmission

, Volume 117, Issue 6, pp 759–763 | Cite as

Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox® or Dysport®

  • Katja Kollewe
  • Bahram Mohammadi
  • Reinhard Dengler
  • Dirk Dressler
Movement Disorders-Original Article


Botulinum toxin is considered the treatment of choice for hemifacial spasm (HFS) and reinnervation synkinesias (RS). We present 133 patients with HFS (n = 97) and RS (n = 36) who have been treated with either Botox® (n = 78) or Dysport® (n = 55) exclusively for 6 years (range 2–12 years). The Botox® dose was 21 ± 8 MU, the Dysport® dose 46 ± 22 MU. The therapeutic effect started after 7.1 ± 2.3 days and lasted for 12.5 ± 3.9 weeks. It was stable throughout the observation period in 85% of all patients. Adverse effects occurred in 5.4% of injection series. No patient terminated treatment because of unsatisfactory results. Secondary therapy failure did not occur. With an effective conversion ratio of Botox®:Dysport® = 1:2.56 there were no differences between both drugs with respect to therapeutic efficacy and adverse effects thus confirming the hypothesis that there may not be intrinsic differences between both products.


Hemifacial spasm Reinnervation sykinesias Botulinum toxin Conversion factor Botox® Dysport® 


  1. Adler CH, Zimmerman RA, Savino PJ, Bernardi B, Bosley TM, Sergott RC (1992) Hemifacial spasm: evaluation by magnetic resonance imaging and magnetic resonance tomographic angiography. Ann Neurol 32(4):502–506CrossRefPubMedGoogle Scholar
  2. Ainsworth JR, Kraft SP (1995) Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm. Ophthalmology 102(12):2036–2040PubMedGoogle Scholar
  3. Baker RS, Stava MW, Nelson KR, May PJ, Huffman MD, Porter JD (1994) Aberrant reinnervation of facial musculature in a subhuman primate: a correlative analysis of eyelid kinematics, muscle synkinesis, and motoneuron localization. Neurology 44(11):2165–2173PubMedGoogle Scholar
  4. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A (2009) Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol 16(3):392–398CrossRefPubMedGoogle Scholar
  5. Bills DC, Hanieh A (1991) Hemifacial spasm in an infant due to fourth ventricular ganglioglioma. Case report. J Neurosurg 75(1):134–137CrossRefPubMedGoogle Scholar
  6. Brin MF, Blitzer A (1993) Botulinum toxin: dangerous terminology errors. J R Soc Med 86(8):493–494PubMedGoogle Scholar
  7. Chen HJ, Lee TC, Lui CC (1996) Hemifacial spasm caused by a venous angioma. Case report. J Neurosurg 85(4):716–717CrossRefPubMedGoogle Scholar
  8. Colosimo C, Bologna M, Lamberti S, Avanzino L, Marinelli L, Fabbrini G, Abbruzzese G, Defazio G, Berardelli A (2006) A comparative study of primary and secondary hemifacial spasm. Arch Neurol 63(3):441–444CrossRefPubMedGoogle Scholar
  9. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev 2005(1):CD004899Google Scholar
  10. Defazio G, Abbruzzese G, Girlanda P, Vacca L, Curra A, De Salvia R, Marchese R, Raineri R, Roselli F, Livrea P, Berardelli A (2002) Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 59(3):418–420CrossRefPubMedGoogle Scholar
  11. Digre K, Corbett JJ (1988) Hemifacial spasm: differential diagnosis, mechanism, and treatment. Adv Neurol 49:151–176PubMedGoogle Scholar
  12. Elston JS (1992) The management of blepharospasm and hemifacial spasm. J Neurol 239(1):5–8CrossRefPubMedGoogle Scholar
  13. Flanders M, Chin D, Boghen D (1993) Botulinum toxin: preferred treatment for hemifacial spasm. Eur Neurol 33(4):316–319CrossRefPubMedGoogle Scholar
  14. Galvez-Jimenez N, Hanson MR, Desai M (2001) Unusual causes of hemifacial spasm. Sem Neurol 21(1):75–83CrossRefGoogle Scholar
  15. Girard N, Poncet M, Caces F, Tallon Y, Chays A, Martin-Bouyer P, Magnan J, Raybaud C (1997) Three-dimensional MRI of hemifacial spasm with surgical correlation. Neuroradiology 39(1):46–51CrossRefPubMedGoogle Scholar
  16. Gomez-Perals LF, Ortega-Martinez M, Fernandez-Portales I, Cabezudo-Artero JM (2005) Hemifacial spasm as clinical presentation of intracranial meningiomas. Report of three cases and review of the literature. Neurocirugia (Astur) 16(1):21–25 discussion 26Google Scholar
  17. Hambleton P, Pickett AM (1994) Potency equivalence of botulinum toxin preparations. J R Soc Med 87(11):719PubMedGoogle Scholar
  18. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17(6):1288–1293CrossRefPubMedGoogle Scholar
  19. Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45(9):1743–1746PubMedGoogle Scholar
  20. Jitpimolmard S, Tiamkao S, Laopaiboon M (1998) Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 64(6):751–757CrossRefPubMedGoogle Scholar
  21. Kenney C, Jankovic J (2008) Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 115(4):585–591CrossRefPubMedGoogle Scholar
  22. Kobata H, Kondo A, Iwasaki K, Nishioka T (1998) Combined hyperactive dysfunction syndrome of the cranial nerves: trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia: 11-year experience and review. Neurosurgery 43(6):1351–1361 discussion 1361–1352CrossRefPubMedGoogle Scholar
  23. Kraft SP, Lang AE (1988) Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. Can J Neurol Sci 15(3):276–280PubMedGoogle Scholar
  24. Kranz G, Haubenberger D, Voller B, Posch M, Schnider P, Auff E, Sycha T (2009) Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord 24(2):231–236CrossRefPubMedGoogle Scholar
  25. Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Ruzicka E, Jech R, Slawek J, Ahmed F (2005) Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 20(8):937–944CrossRefPubMedGoogle Scholar
  26. Matsumoto K, Kimura S, Kakita K (2005) Endovascular treatment of vertebral artery aneurysm manifesting as progressive hemifacial spasm. Neurologia Medico-Chirurgica 45(7):360–362CrossRefPubMedGoogle Scholar
  27. Mauriello JA Jr, Leone T, Dhillon S, Pakeman B, Mostafavi R, Yepez MC (1996) Treatment choices of 119 patients with hemifacial spasm over 11 years. Clin Neurol Neurosurg 98(3):213–216CrossRefPubMedGoogle Scholar
  28. McLaughlin MR, Jannetta PJ, Clyde BL, Subach BR, Comey CH, Resnick DK (1999) Microvascular decompression of cranial nerves: lessons learned after 4400 operations. J Neurosurg 90(1):1–8CrossRefPubMedGoogle Scholar
  29. Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592–597CrossRefPubMedGoogle Scholar
  30. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009a) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31(5):463–466Google Scholar
  31. Mohammadi B, Kollewe K, Wegener M, Bigalke H, Dengler R (2009b) Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J Neural Transm 116(4):437–441CrossRefPubMedGoogle Scholar
  32. Nagata S, Fujii K, Nomura T, Matsushima T, Fukui M, Yasumori K (1991) Hemifacial spasm caused by CP angle AVM associated with ruptured aneurysm in the feeding artery—case report. Neurologia Medico-Chirurgica 31(7):406–409CrossRefPubMedGoogle Scholar
  33. Nagata S, Matsushima T, Fujii K, Fukui M, Kuromatsu C (1992) Hemifacial spasm due to tumor, aneurysm, or arteriovenous malformation. Surg Neurol 38(3):204–209CrossRefPubMedGoogle Scholar
  34. Neimat JS, Hoh BL, McKenna MJ, Rabinov JD, Ogilvy CS (2005) Aneurysmal expansion presenting as facial weakness: case report and review of the literature. Neurosurgery 56(1):190PubMedGoogle Scholar
  35. Papanagiotou P, Grunwald IQ, Politi M, Struffert T, Ahlhelm F, Reith W (2006) Vascular anomalies of the cerebellopontine angle. Der Radiologe 46(3):216–222CrossRefPubMedGoogle Scholar
  36. Park YC, Lim JK, Lee DK, Yi SD (1993) Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 8(5):334–340PubMedGoogle Scholar
  37. Pickett AM, Hambleton P (1994) Dose standardisation of botulinum toxin. Lancet 344(8920):474–475CrossRefPubMedGoogle Scholar
  38. Platania N, Nicoletti GF, Barbagallo G, Albanese V (1997) Concurrent trigeminal and glossopharyngeal neuralgia, hemifacial spasm and hypertension by neurovascular compression. Case report. J Neurosurg Sci 41(3):303–307PubMedGoogle Scholar
  39. Poungvarin N, Viriyavejakul A (1992) Two hundred and fifty patients with hemifacial spasm treated with botulinum toxin injection. J Med Assoc Thai 75(4):199–203PubMedGoogle Scholar
  40. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72(4):459–462PubMedGoogle Scholar
  41. Rapana A, Guida F, Conti C, Rizzo G, Trincia G (1999) Ependymoma of the fourth ventricle presenting with hemifacial spasm. Report of a case. Revue Neurologique 155(4):309–311PubMedGoogle Scholar
  42. Rhee BA, Kim TS, Kim GK, Leem WL (1995) Hemifacial spasm caused by contralateral cerebellopontine angle meningioma: case report. Neurosurgery 36(2):393–395CrossRefPubMedGoogle Scholar
  43. Rollnik JD, Matzke M, Wohlfarth K, Dengler R, Bigalke H (2000) Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. Eur Neurol 43(1):9–12CrossRefPubMedGoogle Scholar
  44. Sade B, Mohr G, Dufour JJ (2005) Cerebellopontine angle lipoma presenting with hemifacial spasm: case report and review of the literature. J Otolaryngol 34(4):270–273CrossRefPubMedGoogle Scholar
  45. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, Bastos-Lima A, Martins R, Castro-Caldas A (1997) DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A–Dysport and Botox–assuming a ratio of 4:1. Mov Disord 12(6):1013–1018CrossRefPubMedGoogle Scholar
  46. Sandberg DI, Souweidane MM (1999) Hemifacial spasm caused by a pilocytic astrocytoma of the fourth ventricle. Pediatr Neurol 21(4):754–756CrossRefPubMedGoogle Scholar
  47. Sprik C, Wirtschafter JD (1988) Hemifacial spasm due to intracranial tumor. An international survey of botulinum toxin investigators. Ophthalmology 95(8):1042–1045PubMedGoogle Scholar
  48. Tan EK, Chan LL, Lim SH, Lim WE, Khoo JB, Tan KP (1999) Role of magnetic resonance imaging and magnetic resonance angiography in patients with hemifacial spasm. Ann Acad Med Singap 28(2):169–173PubMedGoogle Scholar
  49. Taylor JD, Kraft SP, Kazdan MS, Flanders M, Cadera W, Orton RB (1991) Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol 26(3):133–138PubMedGoogle Scholar
  50. Thomander L (1984) Reorganization of the facial motor nucleus after peripheral nerve regeneration. An HRP study in the rat. Acta Otolaryngol 97(5–6):619–626CrossRefPubMedGoogle Scholar
  51. Uchino M, Nomoto J, Ohtsuka T, Kuramitsu T (2005) Fusiform aneurysm of the vertebral artery presenting with hemifacial spasm treated by microvascular decompression. Acta Neurochir 147(8):901–903CrossRefGoogle Scholar
  52. Vogt T, Lussi F, Paul A, Urban P (2008) Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A. Der Nervenarzt 79(8):912–917CrossRefPubMedGoogle Scholar
  53. Wang A, Jankovic J (1998) Hemifacial spasm: clinical findings and treatment. Muscle Nerve 21(12):1740–1747CrossRefPubMedGoogle Scholar
  54. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D (2009) Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 25(7):1573–1584CrossRefPubMedGoogle Scholar
  55. Yoshimura DM, Aminoff MJ, Tami TA, Scott AB (1992) Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 15(9):1045–1049CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Katja Kollewe
    • 1
  • Bahram Mohammadi
    • 1
  • Reinhard Dengler
    • 1
  • Dirk Dressler
    • 1
  1. 1.Movement Disorders Section, Department of NeurologyHannover Medical SchoolHannoverGermany

Personalised recommendations